Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP11 versus Xolair in chronic spontaneous urticaria refractory to H1 antihistamines
2024-514764-72-00Phase 3Completed
- Sponsor
- CuraTeQ Biologics
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of omalizumab in chronic idiopathic urticaria (CIU) (3 arms), sponsored by CuraTeQ Biologics. Primary endpoint: Change from baseline in weekly Itch Severity Score (ISS7) at Week 12. Started Aug 2024; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2024-514764-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514764-72-00.